Literature DB >> 31343789

Pretreatment Posttraumatic Stress Disorder Symptom Network Metrics Predict the Strength of the Association Between Node Change and Network Change During Treatment.

Santiago Papini1, Mikael Rubin1, Michael J Telch1, Jasper A J Smits1, Denise A Hien2,3.   

Abstract

Network analysis has been increasingly applied in an effort to understand complex interactions among symptoms in posttraumatic stress disorder (PTSD). Although methods that initially focused on identifying central symptoms in cross-sectional networks have been extended to longitudinal data that can reveal the relative roles of acute symptoms in the emergence of the PTSD syndrome, the association between network metrics and symptom change during treatment have yet to be explored in PTSD. To address this gap, we estimated pretreatment PTSD symptom networks in a sample of patients from a multisite clinical trial for women with full or subthreshold PTSD and substance use. We tested the hypothesis that node metrics calculated in the pretreatment network would be predictive of the strength of the association between a symptom's change and the change in the severity of all other symptoms through the course of treatment. A symptom node's strength and predictability in the pretreatment network were each strongly correlated with the association between that symptom's change and overall change across the symptom network, r(15) = .79, p < .001 and r(15) = .75, p < .001, respectively, whereas a symptom's mean severity at pretreatment was not, r(15) = .27, p = .292. These findings suggest that a node's centrality prior to treatment engagement is a predictor of its association with overall symptom change throughout the treatment process.
© 2019 International Society for Traumatic Stress Studies.

Entities:  

Mesh:

Year:  2019        PMID: 31343789     DOI: 10.1002/jts.22379

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  7 in total

1.  Symptom structure of PTSD and co-morbid depressive symptoms - a network analysis of combat veteran patients.

Authors:  Amit Lazarov; Benjamin Suarez-Jimenez; Ofir Levi; Daniel D L Coppersmith; Gadi Lubin; Daniel S Pine; Yair Bar-Haim; Rany Abend; Yuval Neria
Journal:  Psychol Med       Date:  2019-08-27       Impact factor: 7.723

2.  Network analysis reveals the associations of past quit experiences on current smoking behavior and motivation to quit.

Authors:  Christina D Dutcher; Santiago Papini; Catherine S Gebhardt; Jasper A J Smits
Journal:  Addict Behav       Date:  2020-10-01       Impact factor: 3.913

3.  The importance of transdiagnostic symptom level assessment to understanding prognosis for depressed adults: analysis of data from six randomised control trials.

Authors:  C O'Driscoll; J E J Buckman; E I Fried; R Saunders; Z D Cohen; G Ambler; R J DeRubeis; S Gilbody; S D Hollon; T Kendrick; D Kessler; G Lewis; E Watkins; N Wiles; S Pilling
Journal:  BMC Med       Date:  2021-05-06       Impact factor: 8.775

4.  Excessive Worrying as a Central Feature of Anxiety during the First COVID-19 Lockdown-Phase in Belgium: Insights from a Network Approach.

Authors:  Alexandre Heeren; Bernard Hanseeuw; Louise-Amélie Cougnon; Grégoire Lits
Journal:  Psychol Belg       Date:  2021-12-30

5.  Validation of the Social Media Disorder Scale using network analysis in a large representative sample of Czech adolescents.

Authors:  Nika Šablatúrová; Karel Rečka; Lukas Blinka
Journal:  Front Public Health       Date:  2022-08-22

6.  COVID-19 lockdown has altered the dynamics between affective symptoms and social isolation among older adults: results from a longitudinal network analysis.

Authors:  Junhong Yu; Rathi Mahendran
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

7.  On the validity of the centrality hypothesis in cross-sectional between-subject networks of psychopathology.

Authors:  Tobias R Spiller; Ofir Levi; Yuval Neria; Benjamin Suarez-Jimenez; Yair Bar-Haim; Amit Lazarov
Journal:  BMC Med       Date:  2020-10-12       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.